Trends in treatment of non-small cell lung cancer in Finland 2014–2019

Introduction: Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality in the Western world. However, emerging treatment options and more patients directed to active treatments might improve the outcomes. Here, we retrospectively studied the patient characteristics and treatment practices for NSCLC in Finland 2014–2019 with a special focus on changes in trends over time. Material and methods: The cohort consisted of patients diagnosed with NSCLC in Finland 2014–2018. Cancer treatments for the patients were followed until the end of 2019. The data, both structured and unstructured, were collected from electronic medical records of four university hospitals in Finland Results: Of the study population (n = 4047), 65% had adenocarcinoma and 29% squamous cell carcinoma. The share of patients who had not received any active treatment (except palliative radiotherapy) decreased from 32% to 18% between 2014–18. The percentage of patients receiving surgery increased slightly from 22.7% to 24% and for patients receiving chemotherapy or immuno-oncological (IO) treatments from 29% to 41.2% and from 0.8% to 8%, respectively between, 2014–18. However, the time of treatment for patients receiving systemic cancer treatments did not change during the same time period. Discussion: The current study suggests a trend in NSCLC towards more active treatment approaches in 2014–18.